Answers are grounded in this paper and cite their sources.
It's in the blood. Analogues (see formula) of the non-steroidal inflammatory drug Sulindac are potent and selective inhibitors of the angiogenesis-related receptor tyrosine kinases VEGFR-2 and -3, IGF1R, FGF1R and Tie-2; this suggests a possible link between the antiangiogenic properties of Sulindac metabolites and kinase inhibition.
No takes yet. Share an insight, caveat, or question.
Gourzoulidou et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: